Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Gary L. Pattee, Angela Genge, Philippe Couratier, Christian Lunetta, Gen Sobue, Masashi Aoki, Hiide Yoshino, Carlayne E. Jackson, James Wymer, Alejandro Salah & Sally Nelson. (2023) Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis. Expert Review of Neurotherapeutics 0:0, pages 1-8.
Read now
Read now
I. Giovannelli, P. Heath, P. J. Shaw & J. Kirby. (2020) The involvement of regulatory T cells in amyotrophic lateral sclerosis and their therapeutic potential. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21:5-6, pages 435-444.
Read now
Read now
Hideyuki Sawada. (2019) Considerations for pharmacotherapy use in patients with amyotrophic lateral sclerosis: the earlier it starts, the better the results. Expert Opinion on Pharmacotherapy 20:14, pages 1671-1674.
Read now
Read now
Joseph M. Palumbo, Jean Hubble, Stephen Apple, Koji Takei, Kikumi Tsuda, Shawn Liu, Jeffrey Zhang & Wendy Agnese. (2019) Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:5-6, pages 421-431.
Read now
Read now
. (2018) Theme 9 Clinical trials and trial design. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:sup1, pages 264-281.
Read now
Read now
Alexander McGown & Matthew John Stopford. (2018) High-throughput drug screens for amyotrophic lateral sclerosis drug discovery. Expert Opinion on Drug Discovery 13:11, pages 1015-1025.
Read now
Read now
Koji Takei, Kikumi Tsuda, Fumihiro Takahashi & Joseph Palumbo. (2017) Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 64-70.
Read now
Read now
Nicholas J. Maragakis. (2017) What can we learn from the edaravone development program for ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 98-103.
Read now
Read now
Koji Takei, Kazutoshi Watanabe, Satoshi Yuki, Makoto Akimoto, Takeshi Sakata & Joseph Palumbo. (2017) Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 5-10.
Read now
Read now
Yoshinobu Nakamaru, Shuji Kinoshita, Atsuhiro Kawaguchi, Koji Takei, Joseph Palumbo & Masayuki Suzuki. (2017) Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 80-87.
Read now
Read now
Articles from other publishers (32)
Benjamin Rix Brooks, Erik P. Pioro, Takeshi Sakata, Fumihiro Takahashi, Melissa Hagan & Stephen Apple. (2023) The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis. Muscle & Nerve.
Crossref
Crossref
Shotaro Haji, Koji Fujita, Ryosuke Oki, Yusuke Osaki, Ryosuke Miyamoto, Hiroyuki Morino, Seiichi Nagano, Naoki Atsuta, Yuki Kanazawa, Yuki Matsumoto, Atsuko Arisawa, Hisashi Kawai, Yasutaka Sato, Satoshi Sakaguchi, Kenta Yagi, Tatsuto Hamatani, Tatsuo Kagimura, Hiroaki Yanagawa, Hideki Mochizuki, Manabu Doyu, Gen Sobue, Masafumi Harada & Yuishin Izumi. (2023) An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study. JMIR Research Protocols 12, pages e42032.
Crossref
Crossref
Mengxia Gao, Lingqun Zhu, Jingling Chang, Tianyu Cao, Lianying Song, Chunli Wen, Yi Chen, Yudi Zhuo & Fei Chen. (2022) Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. Clinical Drug Investigation 43:1, pages 1-11.
Crossref
Crossref
Fumihiro Takahashi, Osamu Kano, Yoshito Nagano, Takatomo Yoneoka, Sally Nelson & Yoshiteru Ushirogawa. (2022)
Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies
MCI186
‐16,
MCI186
‐17, and
MCI186
‐19
. Muscle & Nerve 66:5, pages 583-592.
Crossref
Crossref
Stephen A. Johnson, Ton Fang, Fabiola De Marchi, Dylan Neel, Donatienne Van Weehaeghe, James D. Berry & Sabrina Paganoni. (2022) Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. Drugs 82:13, pages 1367-1388.
Crossref
Crossref
Maleesha Jayasinghe, Rahul Jena, Malay Singhal, Samiksha Jain, Snigdha Karnakoti, Minollie Suzanne Silva & Abdul Mueez Alam Kayani. (2022) Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis. Cureus.
Crossref
Crossref
Benjamin Rix Brooks, Terry Heiman-Patterson, Martina Wiedau-Pazos, Shawn Liu, Jeffrey Zhang & Stephen Apple. (2022) Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. PLOS ONE 17:6, pages e0258614.
Crossref
Crossref
Benjamin Rix Brooks, Erik P. Pioro, Jonathan Katz, Fumihiro Takahashi, Koji Takei, Jeffrey Zhang & Stephen Apple. (2021)
Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of
ALSFRS‐R
item scores in pivotal study
MCI186
‐19
. Muscle & Nerve 65:2, pages 180-186.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Kaori Yoshida, Manabu Hirai, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development 10:10, pages 1188-1197.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Yoichi Shiide, Hideaki Matsuda, Makoto Akimoto, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Clinical Pharmacology in Drug Development 10:10, pages 1174-1187.
Crossref
Crossref
Ilaria Giovannelli, Nadhim Bayatti, Abigail Brown, Dennis Wang, Marius Mickunas, William Camu, Jean-Luc Veyrune, Christine Payan, Cecilia Garlanda, Massimo Locati, Raul Juntas-Morales, Nicolas Pageot, Andrea Malaspina, Ulf Andreasson, Carey Suehs, Safa Saker, Christophe Masseguin, John de Vos, Henrik Zetterberg, Ammar Al-Chalabi, P Nigel Leigh, Timothy Tree, Gilbert Bensimon, Paul R Heath, Pamela J Shaw & Janine Kirby. (2021) Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Communications 3:3.
Crossref
Crossref
Kaoru Ishizaki, Kenta Yoshimura, Kengo Yoshida, Masao Matsuda, Yutaka Kawaguchi, Satoshi Yuki & Gen Sobue. (2021) Real‐world safety of the novel, free radical scavenger edaravone for amyotrophic lateral sclerosis patients: Data from the post‐marketing surveillance SUNRISE Japan. Neurology and Clinical Neuroscience 9:3, pages 223-229.
Crossref
Crossref
Jessica R. Morrice, Michael Kuo & Christopher A. Shaw. 2021. Spectrums of Amyotrophic Lateral Sclerosis. Spectrums of Amyotrophic Lateral Sclerosis
181
199
.
Zaynab Shakkour, Hawraa Issa, Helene Ismail, Ohanes Ashekyan, Karl John Habashy, Leila Nasrallah, Hussam Jourdi, Eva Hamade, Stefania Mondello, Mirna Sabra, Kazem Zibara & Firas Kobeissy. (2021) Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury. Current Medicinal Chemistry 28:12, pages 2369-2391.
Crossref
Crossref
Raheem Fazal, Steven Boeynaems, Ann Swijsen, Mathias De Decker, Laura Fumagalli, Matthieu Moisse, Joni Vanneste, Wenting Guo, Ruben Boon, Thomas Vercruysse, Kristel Eggermont, Bart Swinnen, Jimmy Beckers, Donya Pakravan, Tijs Vandoorne, Pieter Vanden Berghe, Catherine Verfaillie, Ludo Van Den Bosch & Philip Van Damme. (2021)
HDAC6 inhibition restores TDP‐43 pathology and axonal transport defects in human motor neurons with
TARDBP
mutations
. The EMBO Journal 40:7.
Crossref
Crossref
Cyril Jones Jagaraj, Sonam Parakh & Julie D. Atkin. (2021) Emerging Evidence Highlighting the Importance of Redox Dysregulation in the Pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Frontiers in Cellular Neuroscience 14.
Crossref
Crossref
Ammar Al-Chalabi, Adriano Chiò, Charlotte Merrill, Gerry Oster, Rebecca Bornheimer, Wendy Agnese & Stephen Apple. (2021) Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. Journal of Neurology, Neurosurgery & Psychiatry 92:2, pages 165-171.
Crossref
Crossref
Bhaskar Roy & Robert Griggs. (2021) Advances in Treatments in Muscular Dystrophies and Motor Neuron Disorders. Neurologic Clinics 39:1, pages 87-112.
Crossref
Crossref
Hidetoshi Shimizu, Shinsuke Inoue, Mai Endo, Yoshinobu Nakamaru, Kaori Yoshida, Tomoko Natori, Masae Kakubari, Makoto Akimoto & Kazuoki Kondo. (2020) A Randomized, Single‐Blind, Placebo‐Controlled, 3‐Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects. Clinical Pharmacology in Drug Development 10:1, pages 46-56.
Crossref
Crossref
Teresa Cunha-Oliveira, Liliana Montezinho, Catarina Mendes, Omidreza Firuzi, Luciano Saso, Paulo J. Oliveira & Filomena S. G. Silva. (2020) Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention. Oxidative Medicine and Cellular Longevity 2020, pages 1-29.
Crossref
Crossref
Elyse A. EverettElizabeth PedowitzSamuel MaiserJoss CohenJessica BesbrisAmbereen K. MehtaLuqi ChiChristopher A. Jones. (2020) Top Ten Tips Palliative Care Clinicians Should Know About Amyotrophic Lateral Sclerosis. Journal of Palliative Medicine 23:6, pages 842-847.
Crossref
Crossref
Beata Chełstowska & Magdalena Kuźma-Kozakiewicz. (2020) Biochemical parameters in determination of nutritional status in amyotrophic lateral sclerosis. Neurological Sciences 41:5, pages 1115-1124.
Crossref
Crossref
B. Jane Distad & Michael D. Weiss. (2019) Edaravone for amyotrophic lateral sclerosis: More evidence for long‐term benefit. Muscle & Nerve 61:2, pages 129-130.
Crossref
Crossref
Jeremy Shefner, Terry Heiman‐Patterson, Erik P. Pioro, Martina Wiedau‐Pazos, Shawn Liu, Jeffrey Zhang, Wendy Agnese & Stephen Apple. (2019) Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19). Muscle & Nerve 61:2, pages 218-221.
Crossref
Crossref
Tereza Filipi, Zuzana Hermanova, Jana Tureckova, Ondrej Vanatko & Miroslava Anderova. (2020) Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. Journal of Clinical Medicine 9:1, pages 261.
Crossref
Crossref
Arash Jalali-Sohi, Leila Darki & Said R Beydoun. (2020) A Retrospective Review to Evaluate the Demographics and Management Profile of Patients with Amyotrophic Lateral Sclerosis Attending a Multidisciplinary Clinic. US Neurology 16:2, pages 110.
Crossref
Crossref
L. McGurk, J. Mojsilovic-Petrovic, V. M. Van Deerlin, J. Shorter, R. G. Kalb, V. M. Lee, J. Q. Trojanowski, E. B. Lee & N. M. Bonini. (2018) Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis. Acta Neuropathologica Communications 6:1.
Crossref
Crossref
Rocio Garcia-Santibanez, Matthew Burford & Robert C. Bucelli. (2018) Hereditary Motor Neuropathies and Amyotrophic Lateral Sclerosis: a Molecular and Clinical Update. Current Neurology and Neuroscience Reports 18:12.
Crossref
Crossref
Jolien Steyaert, Wendy Scheveneels, Joni Vanneste, Philip Van Damme, Wim Robberecht, Patrick Callaerts, Elke Bogaert & Ludo Van Den Bosch. (2018) FUS-induced neurotoxicity in Drosophila is prevented by downregulating nucleocytoplasmic transport proteins. Human Molecular Genetics.
Crossref
Crossref
Naoki Atsuta, Atsushi Hashizume, Gen Sobue & Masahisa Katsuno. (2018) IV. Motor neuron diseasesIV．運動ニューロン疾患. Nihon Naika Gakkai Zasshi 107:8, pages 1477-1485.
Crossref
Crossref
Masamitsu Okada, Satoshi Yamashita, Hidetsugu Ueyama, Masatoshi Ishizaki, Yasushi Maeda & Yukio Ando. (2018) Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci 11, pages 11-14.
Crossref
Crossref
Said R Beydoun & Jeffrey Rosenfeld. (2018) Edaravone in Amyotrophic Lateral Sclerosis’Lessons from the Clinical Development Program and the Importance of a Strategic Clinical Trial Design. US Neurology 14:1, pages 47.
Crossref
Crossref